US 9,809,823 B2
DNA aptamers for promoting remyelination
Louis J. Maher, III, Rochester, MN (US); and Moses Rodriguez, Rochester, MN (US)
Assigned to Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed by Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed on Oct. 10, 2016, as Appl. No. 15/289,359.
Application 15/289,359 is a continuation of application No. 14/837,513, filed on Aug. 27, 2015, granted, now 9,481,887.
Application 14/837,513 is a continuation of application No. 14/114,392, granted, now 9,150,867, issued on Oct. 6, 2015, previously published as PCT/US2012/035005, filed on Apr. 25, 2012.
Claims priority of provisional application 61/565,144, filed on Nov. 30, 2011.
Claims priority of provisional application 61/480,179, filed on Apr. 28, 2011.
Prior Publication US 2017/0088839 A1, Mar. 30, 2017
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 21/02 (2006.01); C07H 21/04 (2006.01); A61K 31/70 (2006.01); C12N 15/115 (2010.01); C12N 5/00 (2006.01)
CPC C12N 15/115 (2013.01) [C12N 2310/16 (2013.01)] 10 Claims
 
1. A method for treating a subject identified as having multiple sclerosis, comprising administering to the subject a pharmaceutical composition comprising a multimeric nucleic acid aptamer in an amount effective to promote remyelination, wherein the nucleic acid aptamer comprises the sequence set forth in SEQ ID NO:17.